FBXL17

Across TCGA pan-cancer cohorts, FBXL17 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FBXL17 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FBXL17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXL17 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where FBXL17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.839	1.000	<.001	63	view →
PDAC	DFS	Median	All	0.868	0.668	.009	28	view →
UCEC	OS	Tertile	All	1.000	0.848	.010	14	view →
LUAD	DFS	Quartile	All	0.886	0.956	.011	7	view →
CCRCC	DFS	Quartile	II,III,IV	0.183	1.000	.024	5	view →
HNSC	OS	Median	All	0.796	0.906	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FBXL17–LSCC (DFS)

Open the LSCC breakdown →